Oxycodone extended-release/abuse-resistant - Collegium Pharmaceutical
Alternative Names: COL-003; Oxycodone abuse resistant - Collegium Pharmaceutical; Oxycodone DETERx®; Oxycodone DETERx®ER; Oxycodone DETERx®extended-release; Oxycodone extended release - Collegium pharmaceutical; XTAMPZA ERLatest Information Update: 28 Dec 2022
At a glance
- Originator Collegium Pharmaceutical
- Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pain
Most Recent Events
- 28 Dec 2022 Discontinued - Clinical-Phase-Unknown for Pain in USA (IV)
- 28 Dec 2020 No recent reports of development identified for clinical-Phase-Unknown development in Pain in USA (IV)
- 30 Sep 2020 9304239: Patent info added